Applications of ML are not limited by modality, and as the technology matures, it may become an integral part of all biopharmaceutical research rather than a distinct category of biotechs.
Applications of ML are not limited by modality, and as the technology matures, it may become an integral part of all biopharmaceutical research rather than a distinct category of biotechs. McKinsey analysis saw an increasing number of biotechs across platform areas integrating machine learning into their R&D processes.8For more on the potential impact of machine learning and AI in life sciences, see “;) The future of biotech: AI-driven drug discovery,” McKinsey, accessed November 10, 2023. Early-stage AI biotech start-ups funded in 2022 have focused on areas including the following: